Alnylam Pharmaceuticals (ALNY) Free Cash Flow (QoQ) (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) Free Cash Flow (QoQ) (2009 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Alnylam Pharmaceuticals | 37.29 Bn | 34.28 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -57.48% |
| Dec 31, 2025 | -66.21% |
| Sep 30, 2025 | 139.52% |
| Jun 30, 2025 | 209.40% |
| Mar 31, 2025 | -24.60% |
| Dec 31, 2024 | -629.72% |
| Sep 30, 2024 | -84.37% |
| Jun 30, 2024 | 249.64% |
| Mar 31, 2024 | -729.66% |
| Dec 31, 2023 | -96.11% |
| Sep 30, 2023 | 557.01% |
| Jun 30, 2023 | 58.47% |
| Mar 31, 2023 | 8.85% |
| Dec 31, 2022 | -126.08% |
| Sep 30, 2022 | 36.97% |
| Jun 30, 2022 | 26.54% |
| Mar 31, 2022 | -73.04% |
| Dec 31, 2021 | 31.76% |
| Sep 30, 2021 | -11.96% |
| Jun 30, 2021 | 41.14% |